In September 2026, an interesting article was published about the need for improvements in ways to predict MPN disease progression.
The authors, a group of international MPN haematologists including Australia’s Zi Ng, describe how progression prediction in MPNs remains a major unmet need due to the lack of standardised biomarkers, reliable predictive models and validated clinical trial endpoints. They call for “immediate, coordinated action”.
They explain that “Current frameworks lack standardized biomarkers, reliable predictive models, and validated surrogate endpoints—gaps that result in suboptimal patient care and missed therapeutic opportunities.”
Their “summary recommendations for the MPN community are to:
- Integrate clinical, molecular, and inflammatory parameters—such as VAF dynamics, cytokine profiles, and BM fibrosis—into dynamic prognostic models where appropriate.
- Launch prospective trials with extended follow-up and coordinated stakeholder engagement to validate biomarkers and enable identification of disease-modifying therapies.
- Establish standardized protocols for biomarker assessment and clinical trial endpoints.
- Accelerate regulatory engagement to ensure rapid translation of research findings into clinical practice.
- Build the largest prospective MPN patient registry to further address fundamental questions regarding disease progression.”
“The tools, knowledge, and collaborative networks exist to transform MPN care. What is required now is a focused collaborative effort amongst all stakeholders in the community (patients, caregivers, clinicians/researchers, and biopharma). Advancing biomarker-driven approaches is a clinical imperative that will enable earlier intervention, personalized therapeutic strategies, and ultimately, improved clinical outcomes for patients with MPNs at risk of progression.”
The full article Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach has free access.
